These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17347960)

  • 1. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.
    Bellorin-Font E; Vasquez-Rios G; Martin KJ
    Curr Osteoporos Rep; 2019 Oct; 17(5):333-342. PubMed ID: 31485996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of statins for preventing cardiovascular and renal outcomes in patients with chronic kidney disease excluding dialysis: guideline from the Italian Society of Nephrology].
    De Nicola L; Strippoli GF; Ravani P; Del Vecchio L; Cianciaruso B;
    G Ital Nefrol; 2007; 24 Suppl 37():S83-90. PubMed ID: 17347957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in pharmacotherapy for secondary hyperparathyroidism.
    Rodríguez M; Rodríguez-Ortiz ME
    Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Haemoglobin targets for chronic kidney disease: guideline from the Italian Society of Nephrology].
    Canavese C; Strippoli GF; Bonomini M; Triolo G;
    G Ital Nefrol; 2007; 24 Suppl 37():S99-106. PubMed ID: 17347959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antihypertensive agents for the prevention of chronic kidney disease progression: guideline from the Italian Society of Nephrology].
    Del Vecchio L; Manno C; Ravani P; De Nicola L; Cianciaruso B;
    G Ital Nefrol; 2007; 24 Suppl 37():S64-82. PubMed ID: 17347956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
    Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
    Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythropoietins and haemoglobin targets to prevent the progression of chronic kidney disease: guideline from the Italian Society of Nephrology].
    Ravani P; Del Vecchio L; De Nicola L; Cianciaruso B;
    G Ital Nefrol; 2007; 24 Suppl 37():S91-8. PubMed ID: 17347958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of Cinacalcet in chronic kidney disease: a case report].
    Russo R; Argentino G; Maresca ID; Sannino G; Memoli A; Memoli B
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.